BPTH (Bio-Path Holdings) 5-Year EBITDA Growth Rate: 33.30% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Bio-Path Holdings 5-Year EBITDA Growth Rate?

Bio-Path Holdings BPTH -17.58% 5-Year EBITDA Growth Rate is 33.30% as of Mar. 2026. The stock has 1 warning sign investors should review.

Bio-Path Holdings's EBITDA per Share for the three months ended in Mar. 2026 was $-0.03.

During the past 3 years, the average EBITDA Per Share Growth Rate was 45.60% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 33.30% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 30.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Bio-Path Holdings was 50.50% per year. The lowest was -27.70% per year. And the median was 3.50% per year.

Bio-Path Holdings  (OTCPK:BPTH) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Bio-Path Holdings 5-Year EBITDA Growth Rate Related Terms

BPTH vs AZTR, CLDI, BBLG: 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Bio-Path Holdings's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Path Holdings 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Path Holdings's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Bio-Path Holdings's 5-Year EBITDA Growth Rate falls into.


Bio-Path Holdings 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 33.30% mean?
Bio-Path Holdings (BPTH) has a 5-Year EBITDA Growth Rate of 33.30% as of Mar. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Bio-Path Holdings and its competitors.
Is Bio-Path Holdings' 5-Year EBITDA Growth Rate too high?
Bio-Path Holdings' current 5-Year EBITDA Growth Rate is 33.30%.
How does Bio-Path Holdings' 5-Year EBITDA Growth Rate compare to AZTR and CLDI?
Bio-Path Holdings' 5-Year EBITDA Growth Rate of 33.30% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Bio-Path Holdings and its competitors. Bio-Path Holdings's current 5-Year EBITDA Growth Rate is 33.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Path Holdings stock overvalued right now?
Bio-Path Holdings (BPTH) has a current 5-Year EBITDA Growth Rate of 33.30%. The current 5-Year EBITDA Growth Rate is 33.30%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Bio-Path Holdings (BPTH), the current 5-Year EBITDA Growth Rate is 33.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio-Path Holdings Business Description

Address No. 2407, 625 Stanwix Street, Pittsburgh, PA, USA, 15222
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.